Browse by author
Lookup NU author(s): Dr Fiona MalcomsonORCiD,
Professor Linda Sharp,
Professor John Mathers,
Dr Carlos Celis Morales
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2021 American Association for Cancer Research. Background: Few studies have explored the emerging adiposity marker A Body Shape Index (ABSI) with cancer risk. This study investigated the associations between ABSI and the incidence of cancer at 23 sites and all cancer combined. Methods: Data from 442,610 participants from the UK Biobank prospective study were included in this study. ABSI was used as the exposure. Incidence of cancer at 23 sites was the outcome. Cox proportional hazard models were performed to explore the association of ABSI, and combined ABSI and body mass index (BMI) with cancer risk, after adjusting for multiple testing. Results: 36,961 individuals developed cancer during the 8.8 years median follow-up. In multivariable analyses, participants in the highest tertile of ABSI had higher risk of lung [HR, 1.58; 95% confidence interval (CI), 1.44-1.74], liver (HR, 1.45; 95% CI, 1.18-1.77), esophagus (HR, 1.32; 95% CI, 1.12-1.57), colorectal (HR, 1.19; 95% CI, 1.10-1.28), and breast (HR, 1.05; 95% CI, 1.04-1.17) cancers, and all cancers combined (HR, 1.11; 95% CI, 1.08-1.14) compared with the lowest tertile. These associations remained significant after adjustment for BMI. When ABSI was combined with BMI, participants in the highest ABSI who also had a BMI ≥ 25 kg/m2 were at higher risk of uterus, esophagus, liver, stomach, colorectal, and breast cancers, as well as all cancers combined, compared with those in the lowest ABSI tertile with a normal BMI. Conclusions: ABSI is associated with an increased risk of five cancers as well as all cancers combined, independently of BMI.
Author(s): Parra-Soto S, Malcomson FC, Ho FK, Pell JP, Sharp L, Mathers JC, Celis-Morales C
Publication type: Article
Publication status: Published
Journal: Cancer Epidemiology Biomarkers and Prevention
Online publication date: 07/02/2022
Acceptance date: 22/11/2021
ISSN (print): 1055-9965
ISSN (electronic): 1538-7755
Publisher: American Association for Cancer Research Inc.
PubMed id: 34853021
Altmetrics provided by Altmetric